Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase II/III trial tests whether it is possible to decrease the chance of high-grade
B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual
combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by
blocking a protein called Bcl-2. Drugs used in usual chemotherapy, such as rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide, work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving venetoclax together with usual
chemotherapy may work better than usual chemotherapy alone in treating patients with
high-grade B-cell lymphomas, and may increase the chance of cancer going into remission and
not returning.
-
Click here for details...
This phase I trial evaluates the side effects and best dose of lenalidomide when added to
nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central
nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking
the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of cancer cells to grow and spread. Rituximab is a monoclonal
antibody that may interfere with the ability of cancer cells to grow and spread. Methotrexate
is frequently combined with other chemotherapy agents to improve response. This study may
help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma
treatment. In addition, it may help researchers see whether the control of CNS lymphoma can
be extended by using these study drugs as maintenance (prolonged therapy) after control is
achieved with the initial chemotherapy regimen (induction).
-
Click here for details...
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy
consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in
treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as
CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. This trial may help find out if this
approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
-
Click here for details...
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus
chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal
B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may
help the body's immune system attack the cancer, and may interfere with the ability of cancer
cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an
immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth
of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20,
which is found on B cells (a type of white blood cell) and some types of cancer cells. This
may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may
help treat patients with PMBCL.
-
Click here for details...
This randomized phase III trial studies how well crizotinib works in treating patients with
stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation
in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make
it very active and important for tumor cell growth and progression. Crizotinib may stop the
growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an
effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
-
Click here for details...
This phase II trial compares three chemotherapy regimens consisting of bendamustine,
rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating
patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as
bendamustine and cytarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer
cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. This study is being done to find out if one the drug
combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or
worse than the usual approach for mantle cell lymphoma.
-
Click here for details...
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
-
Click here for details...
This randomized phase II trial studies how well obinutuzumab with or without umbralisib,
lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa
follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with
obinutuzumab, may induce changes in body's immune system and may interfere with the ability
of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use
substances made from living organisms that may stimulate or suppress the immune system in
different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and
bendamustine, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination
chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
-
Click here for details...
This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab
vedotin) when given with combination chemotherapy in treating patients with newly diagnosed
stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody,
brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in
a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as
doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. The addition of nivolumab or brentuximab vedotin to combination
chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.
-
Click here for details...
This phase II/III trial compares the side effects and activity of oral azacitidine in
combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide,
doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating
patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP
includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the
lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes
prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy
drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as
oral azacitidine, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without
disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
-
Click here for details...
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed
treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic
lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Starting treatment with the
venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes
for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to
starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
-
Click here for details...
This phase II trial studies the effects of ibrutinib and rituximab with or without venetoclax
in treating patients with previously untreated Waldenstrom's
macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody
that may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop
the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with
previously untreated Waldenstrom's macroglobulinemia than ibrutinib and rituximab alone.
|
